[Development and clinical use of chemical immunomodulators].
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000917:Antibody Formation; D001169:Arthritis, Experimental / Q000628:therapy; D001310:Auranofin; D006051:Aurothioglucose / Q000031:analogs & derivatives / Q000627:therapeutic use; D003095:Collagen Diseases / Q000628:therapy*; D003545:Cysteine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D006168:Guinea Pigs; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D051381:Rats; D062367:ortho-Aminobenzoates / Q000008:administration & dosage / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D062367:ortho-Aminobenzoates; D007978:Levamisole; D006051:Aurothioglucose; D001310:Auranofin; C015735:lobenzarit; D003545:Cysteine; C026535:bucillamine